Search

A recent study by Boehringer Ingelheim Pharma GmbH & Co.KG in Biberach an der Rib, Germany, focuses on reducing structural nonidentifiabilities in upstream bioprocess models using profile likelihood. The research highlights the importance of parameter estimates in model predictions and proposes profile likelihood as a method to determine parameter confidence intervals. The study concludes that profile likelihood is effective in providing reliable estimates for nonlinear models with limited data. For more information, readers can refer to the journal article in Biotechnology and Bioengineering. [Extracted from the article]

A recent study conducted in Ingelheim, Germany, focused on the bioequivalence of pimobendan oral solution and pimobendan chewable tablets in beagle dogs. The research aimed to improve dosing accuracy in small and toy breed dogs diagnosed with myxomatous mitral valve disease. The study found that the novel liquid formulation of pimobendan was bioequivalent to the chewable tablets, supporting accurate dosing for smaller dog breeds. For more information, readers can refer to the Journal of Veterinary Internal Medicine. [Extracted from the article]

Elanco Animal Health Inc. filed a Form 4 with the U.S. Securities and Exchange Commission on January 14, 2025. This filing is a statement of changes in beneficial ownership of securities, as required by the SEC for directors, officers, or owners of more than ten percent of a class of equity securities. The document provides contact information for Elanco Animal Health Inc. and can be accessed on the SEC's website for further details. [Extracted from the article]

CattleGuard Solutions LLC has been issued a patent for a removable sticker that can hold animal health products for livestock tags, making it easy to apply and remove without requiring additional holes in the animal's ear. The sticker can be attached to conventional tags and is designed to release insecticides or other health products over time. This innovation aims to provide a convenient and effective solution for controlling flies and insects on livestock. [Extracted from the article]

A patent application titled "Urine Pcr Assay And Use Thereof To Diagnose And Stage Feline Chronic Kidney Disease" was published online by inventors HAVEN, Michelle Lynn; MOORE, Kristi Mae; PETERSON, Jr., Richard E. The application aims to provide a rapid and reliable diagnostic assay for Feline Chronic Kidney Disease (CKD) using urine samples to detect and stage the disease, especially in early cases. The assay involves using polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR) to amplify and detect fibroblast activation protein (FAP) nucleic acid in urine samples from cats, potentially allowing for early intervention and improved outcomes for affected animals. The patent application was filed by Edge Animal Health Inc. and is available online since January 2, 2025. [Extracted from the article]

Ceres Tag Pty Ltd, based in Samford, Australia, has been granted patent number 12167716 for an animal collar assembly designed by inventor David Ian Smith. The patent addresses the need for an improved animal collar that can monitor an animal's health, behavior, and location, even if the animal escapes from a fenced property. The collar includes an electronic module and a counterweight module to prevent slippage, as well as features like probes for health monitoring and a location tracking device. The invention aims to provide a comfortable and effective solution for pet owners concerned about their animals' well-being and safety. [Extracted from the article]

A patent application titled "Expression Of Eimeria Sequences In Plants And Plant Produced Vaccine For Same" by Mazen Animal Health Inc. aims to address the global issue of coccidiosis in poultry caused by Eimeria parasites. The application focuses on developing a plant-produced vaccine that can provide protection against multiple Eimeria species, reducing the reliance on antibiotics and economic losses in the chicken industry. By orally administering plant-based vaccines containing specific Eimeria antigens, a protective immune response can be induced in animals, offering a potential solution to the challenges posed by current vaccination methods and drug resistance. [Extracted from the article]

Boehringer Ingelheim Animal Health USA Inc. has been issued a patent for a parasiticidal collar containing isoxazoline compounds for the treatment and prevention of parasite infections in animals. The collar may also include tigolaner, a compound with acaracidal and insecticidal properties. The patent describes the composition of the collar, which includes a polymer matrix with isoxazoline active agents and optional additives like plasticizers and stabilizers. This invention aims to provide a long-acting solution for controlling parasite infestations in domesticated animals like cats and dogs. [Extracted from the article]

A recent study conducted by Boehringer Ingelheim Pharma GmbH & Co. KG in Biberach, Germany, explored the relationship between the integrity of the default mode network (DMN) and social dysfunction in mice. The research found that disrupting DMN connectivity through focal demyelination of the forceps minor led to impaired social interactions and increased anxiety in the mice. The study suggests a causal link between DMN integrity and social behavior, with potential implications for precision psychiatry treatments. [Extracted from the article]

The article discusses a patent issued to Substrate Artificial Intelligence SA for methods and apparatus to optimize livestock management using machine learning. The patent aims to automate the process of managing livestock to improve efficiency and reduce costs associated with specialists while maintaining quality care for animals. By utilizing machine learning models, the patent seeks to enhance the health status and bioproduct quality of managed livestock through adaptive feed selection. The invention addresses the need for automated livestock management in the face of technological advancements in intensive livestock management techniques. [Extracted from the article]

Researchers at Boehringer Ingelheim in Germany have conducted a study on bioengineering, specifically focusing on the production of viral products for therapeutic purposes. The research found that a repeated harvest approach resulted in a significant increase in viral yields compared to traditional batch production processes. This study highlights the potential benefits of implementing repeated harvest or perfusion techniques in bioengineering processes to enhance efficiency and reduce costs. For more information, readers can access the full article in Frontiers in Bioengineering and Biotechnology. [Extracted from the article]

A report by Boehringer Ingelheim Pharma GmbH & Co. KG discusses the importance of mechanistic process models in biopharmaceutical development and manufacturing. The research introduces a qualification framework for these models, drawing on existing guidelines and frameworks to support decision-making in process development. The framework aims to harmonize modeling procedures in the industry and establish agreement on the qualification of mechanistic models in biopharmaceutical process development. [Extracted from the article]

The article discusses new findings from Zoetis Inc. on the development of scalable processes for preparing a key chiral, nonracemic intermediate en route to LpxC inhibitors for treating Gram-negative infections. Researchers highlight the importance of addressing drug-resistant Gram-negative bacterial infections as a growing public health concern. The study presents two potentially lower-cost processes for synthesizing the key intermediate, showcasing new chemical approaches that could improve manufacturing safety and efficiency. For more information, readers can contact Zoetis Inc. in Kalamazoo, Michigan. [Extracted from the article]

A study conducted in Parana, Brazil, by Phibro Animal Health Corporation examined the impact of genogroup 4 Infectious Bursal Disease Virus (dIBDV) on vaccinated broiler flocks. The research found that dIBDV can cause health and productivity losses in broilers, with infected flocks experiencing higher mortality rates and worsened feed conversion. The study highlights the importance of monitoring viral variants to prevent outbreaks and improve disease control strategies in the region. [Extracted from the article]

NextPlat Corp is set to showcase OPKO Healthcare products at the 2024 China International Natural Health & Nutrition Expo, Asia's largest exhibition for health, nutrition, and dietary supplements. The event, held at the Wuhan International Expo Center, will feature an array of products from OPKO Health Europe, including veterinary and animal care products. NextPlat aims to expand its sales and promotional activities in China, leveraging online and offline marketing strategies to reach potential retail and distribution partners. OPKO, a global healthcare company, has over 5,500 employees across nine countries and has entered into a distribution agreement with NextPlat's European division as part of their Florida E-commerce Development program. [Extracted from the article]

Boehringer Ingelheim, a global top 20 biopharma company, has committed to transitioning to Veeva Vault CRM in order to enhance its commercial operations and customer experiences. The company aims to launch up to 25 new treatments by 2030 and sees Veeva as a key partner in achieving this goal. Boehringer Ingelheim's move to Veeva Vault CRM reflects its dedication to improving human and animal health through innovative technology solutions. [Extracted from the article]

Elanco Animal Health Incorporated has appointed Dr. Stacey Ma to its Board of Directors, bringing extensive global leadership experience in biopharmaceutical development and manufacturing. Dr. Ma's background in product development and technical operations will enhance Elanco's expertise in these critical areas. With a strong career in the scientific community, Dr. Ma's addition to the board is expected to contribute to Elanco's mission of improving animal health and wellbeing. [Extracted from the article]

Kimberly-Clark Corporation has elected Joseph Romanelli, president of Human Health International for Merck & Co., Inc., to its board of directors. Romanelli brings global leadership experience and expertise in science to the board, expanding it from 12 to 13 directors. With a background in healthcare and pharmaceuticals, Romanelli's appointment aligns with Kimberly-Clark's focus on advancing its Powering Care strategy. [Extracted from the article]

Fidelis Animal Health, Inc. has received FDA approval for Ethiqa XR, an extended-release buprenorphine injectable suspension, to control post-procedural pain in captive rodents and laboratory rabbits. This pharmaceutical-grade medication, utilizing Fidelis Animal Health's Fidelipid LAI technology, provides 72 hours of clinical analgesia with a single subcutaneous injection. Ethiqa XR is compliant with FDA standards and is increasingly used by veterinarians in various institutions and practices across the country. [Extracted from the article]

Recent findings from Boehringer Ingelheim Pharma GmbH & Co. KG have shed light on dosing recommendations for patients with renal impairment in the biotechnology field. The study conducted by the IQ CPLG Organ Impairment WG revealed that pharmaceutical companies lack a consistent methodology for assessing renal function in drug development programs. However, advancements in predicting how kidney function affects drug pharmacokinetics have led to improved dose recommendations and increased participation of patients with impaired kidney function in clinical trials. This research, published in Clinical Pharmacology & Therapeutics, highlights the importance of model-based methods in understanding the impact of kidney function on drug dosing. [Extracted from the article]

The article discusses a study on One Health challenges in urban slums, focusing on antimicrobial resistance (AMR) and other health risks. Researchers used a Patient and Public Involvement (PPI) approach to engage slum residents in Jaipur, Jakarta, Antofagasta, and Istanbul to identify health risks and develop intervention strategies. The study emphasizes the importance of community involvement in addressing interconnected human, environmental, and animal health risks in urban slums, highlighting the need for co-designed interventions for sustainable outcomes. [Extracted from the article]

Phibro Animal Health Corporation reported its financial results for the first quarter ending September 30, 2024, along with updated financial guidance for the year ending June 30, 2025. The highlights included a 13% increase in net sales to $260.4 million, a $15.0 million increase in net income, and a 64% increase in adjusted EBITDA to $30.7 million. Adjusted net income also rose by $8.6 million, with adjusted diluted EPS increasing by $0.21. The company's performance reflects positive growth in the animal health sector. [Extracted from the article]

Phibro Animal Health Corp. recently filed a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) on November 6, 2024. This filing provides unaudited financial statements and offers insight into the company's financial standing throughout the year. The Form 10-Q is a quarterly report that must be submitted by most reporting companies, detailing their financial position for each of the first three fiscal quarters within 45 days of the quarter's end. For more information on this SEC filing, interested individuals can visit the SEC's website. [Extracted from the article]

The patent application by pHi-Tech Animal Health Technologies Ltd. describes an administration device for efficiently administering medicaments to animals, particularly day-old chicks, in the livestock industry. The device includes a holder with clamp members to restrain the animals during administration, ensuring correct dosing and preventing harm. The invention aims to improve the process of medicament administration to large numbers of animals, addressing the need for enhanced devices and methods in the industry. [Extracted from the article]

Boehringer Ingelheim has expanded its research and development facility in Athens, Georgia, with a capital investment of $66.1 million and the creation of 63 new jobs. This state-of-the-art facility is the company's largest animal health site in Georgia and third largest globally, focusing on innovation and improving animal health. The expansion was influenced by partnerships with local institutions and government agencies, reflecting a commitment to sustainability and community collaboration in advancing animal health research and innovation. [Extracted from the article]

Elanco Animal Health Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 16, 2024. This form is used to report material events or corporate changes important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The SEC file number for Elanco Animal Health Inc. is 0001104659-24-108914, and more details can be found on the SEC website. [Extracted from the article]

A study conducted by MSD Animal Health in Boxmeer, Netherlands, focused on the IgM protease of Streptococcus suis as a potential vaccine antigen for pigs. The research identified three evolutionary branches of the IgM protease, with group A showing the highest potential for cross-protective immunity against various serotypes. Experimental vaccines based on the group A IgM protease sequence induced serotype-independent protection in pigs, suggesting potential effectiveness against a significant portion of virulent S. suis strains. The study proposed a new classification system based on IgM protease groups A, B, and C to predict cross-protection outcomes from vaccines. [Extracted from the article]

A study conducted in Barcelona, Spain, focused on detecting and quantifying early infections of Lawsonia intracellularis in suckling piglets, the causative agent of Porcine Proliferative Enteropathy (PPE). The research used molecular techniques to analyze samples from 383 piglets on 16 farms, revealing that some piglets were already infected during the suckling period. The study highlighted the importance of combining real-time qPCR and droplet digital PCR (ddPCR) to improve sensitivity and specificity in detecting L. intracellularis infections. For more information, the study "Detection and quantification by molecular techniques of early infection by Lawsonia intracellularis in suckling piglets" can be found in Porcine Health Management. [Extracted from the article]

A patent has been issued for a stand-alone dispensing pouch designed for storing, transporting, and dispensing fluid veterinary formulations to animals. The inventor aims to provide safe, easy, and stable pouches that address the limitations of current stand-up pouches. The pouch body consists of multiple walls, a top closure with a handle, a bottom closure, front and rear walls, and sidewalls. The pouch is made of flexible film material and includes a fluid dispenser with a one-way valve. The patent was assigned to Boehringer Ingelheim Animal Health USA Inc. [Extracted from the article]

Phibro Animal Health Corp., a company in the pharmaceutical preparations industry, recently filed a Form DEF 14A with the U.S. Securities and Exchange Commission (SEC). This filing is a non-management definitive proxy statement, typically associated with an annual meeting proxy. The company's contact information is provided, and additional information about the filing can be found on the SEC's website. This news article focuses on the business aspect of the filing and mentions the company's involvement in the animal health industry. [Extracted from the article]

Phibro Animal Health Corp., a company in the pharmaceutical preparations industry, recently filed a U.S. Securities and Exchange Commission (SEC) form called DEFA14A. This form is a formal document or financial statement submitted by publicly-traded companies. The filing includes additional proxy soliciting materials-definitive. For more information on this SEC filing, readers can visit the provided link. [Extracted from the article]

A recent study conducted in China by MSD Animal Health has found that feline parvovirus (FPV) continues to be a significant health concern for cats, despite routine vaccination practices. The study analyzed 152 rectal swabs from diseased cats and detected FPV DNA in 17 of the samples. Genetic analysis revealed that the predominant group of FPV in infected cats in China is FPV-G1. The researchers recommend further investigation into the genotypic and evolutionary characteristics of FPV to improve prevention strategies. [Extracted from the article]

A recent study conducted by MSD Animal Health examined the postpartum excretion of internal teat sealant (TS) in dairy cows. The use of TS at dry off is becoming more common to maintain udder health and comply with antibiotic restriction policies in the European Union. The study found that TS residue excretion was higher in cows treated with TS only compared to those treated with antibiotics plus TS. The presence of TS excretion was more likely in multiparous cows, but it was not associated with udder health. The findings provide valuable insights into TS excretion visibility and patterns in dairy cows. [Extracted from the article]

This document is a patent for an aviary system and method for circulating litter in an aviary. The patent aims to address the challenges of maintaining a clean aviary and reducing ammonia levels, which can negatively impact animal and human health. The system involves the use of litter chains and scratching platforms to efficiently provide and circulate fresh litter in the aviary. Additionally, the patent discusses the use of diatomaceous earth as a treatment for parasites in organic animal production. The invention aims to improve the health and productivity of laying hens while reducing labor-intensive tasks. [Extracted from the article]

Acumen Health Holdings, a dietary supplements company focused on eye health, has announced that its subsidiary, PRN Physician Recommended Nutriceuticals, will acquire the assets of the Avenova brand from NovaBay Pharmaceuticals. The Avenova brand offers products for ocular health, including cleansing sprays and wipes. The acquisition is expected to strengthen PRN's portfolio and expand access to Avenova products. This acquisition is part of PRN's strategy to grow in the eye health market. [Extracted from the article]

A recent research article from BASF SE explores the functions and nutritional requirements of vitamins A and E in veterinary medicine and livestock production. The article highlights the importance of these vitamins for vision, immunity, growth, reproduction, and neurological functions in animals. It suggests that liquid formulations of vitamins A and E can effectively address deficiencies and enhance overall animal health and productivity. The research also discusses the potential benefits of injectable forms of these vitamins for livestock and the convenience of administering them through drinking water. The article concludes by suggesting future research directions, such as optimizing formulations and exploring targeted therapies and precision feeding. [Extracted from the article]

Dalan Animal Health, Inc. has announced new experimental findings regarding their bacterial vaccine's potential to reduce Deformed Wing Virus variant B (DWV-B) in honeybee populations. The study showed an 83% reduction in DWV-B levels, independent of mite load. DWV-B is a major variant of the virus that causes deformed wings in honeybees and is transmitted by the Varroa destructor mite. The reduction in virus load is significant as DWV-B is increasingly prevalent worldwide and is associated with overwintering colony losses. The results open up new possibilities for combating viral threats in honeybee populations. [Extracted from the article]

A recent study conducted by researchers at Zoetis Inc. in Kalamazoo, Michigan, has developed a potentially more cost-effective process to prepare a compound called 1-(4-chlorobenzyl)-1H-imidazole-4,5-dicarboxamide (1), which has shown potent anticoccidial activity. Anticoccidials are important for treating parasitic diseases in animals, particularly poultry. The researchers describe the development details for each of the three steps involved in the new process. This research has been peer-reviewed and may be of interest to those studying veterinary research and animal health. [Extracted from the article]

Phibro Animal Health Corporation has released its financial results for the fourth quarter and fiscal year ending June 30, 2024. In the fourth quarter, the company saw an increase in net sales of $18.1 million, or 7%, compared to the same period in the previous year. However, net income decreased by $10.7 million, and diluted earnings per share also decreased. For the full fiscal year, net sales increased by $39.8 million, or 4%, but net income decreased by $30.2 million. Adjusted EBITDA and adjusted net income both saw slight decreases as well. [Extracted from the article]

Elanco Animal Health has announced that the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, a new animal drug. The final 60-day administrative review is now underway. Elanco expects to launch Credelio Quattro in the first quarter of 2025, pending FDA approval. The drug is seeking approval for indications that would provide broad parasite coverage for fleas, ticks, heartworms, and other internal parasites. Elanco also anticipates significant sales from its innovation portfolio in the coming years. [Extracted from the article]

New research conducted in France has explored the microbial communities found in biofilms within livestock buildings and their potential impact on animal health. The study characterized 11 spore-forming strains isolated from broiler chicken farms and found significant genetic and phenotypic diversity among the strains. The research also highlighted the importance of extracellular DNA in the formation of biofilms. These findings provide insights for managing surface microbiota to influence animal health, such as using competitive strains to minimize the establishment of undesirable bacteria or enzymes capable of deconstructing biofilms. [Extracted from the article]

A study published in Parasites & Vectors compared three prescription flea and tick treatment products for dogs: Credelio, Simparica TRIO, and NexGard. The study found that Credelio had the fastest initial speed of tick kill, maintaining this advantage throughout the dosing interval. The lone star tick, known for transmitting dangerous pathogens, was used in the study. Credelio was the only product that significantly reduced ticks compared to the untreated control group, and it maintained a rapid speed of tick kill throughout the entire month-long treatment period. This study establishes Credelio as a front runner in prescription flea and tick treatment products for dogs. [Extracted from the article]

Patterson Companies, a trusted partner for the dental and animal health markets, has released its Corporate Responsibility Report for fiscal year 2024. The report highlights the company's efforts to promote inclusivity in the workplace, reduce its carbon footprint, and implement a diversity, equity, and inclusion (DE&I) strategy. Patterson's CEO, Don Zurbay, expressed pride in the company's progress and emphasized the importance of these initiatives in driving future progress. The report aligns with Patterson's core values of advancement, focus, people-first approach, and passion for serving communities. The full report can be accessed on the company's website. [Extracted from the article]

A recent report from Boehringer Ingelheim RCV highlights the potential of combination therapy in treating KRAS mutant lung and colorectal cancers. The study found that combining a SOS1 inhibitor (SOS1i) called BI-3406 with the KRAS inhibitor adagrasib resulted in stronger antitumor responses compared to adagrasib alone. The combination treatment also delayed the emergence of acquired resistance and showed promise in treating both KRAS inhibitor-naive and relapsed KRAS-mutant tumors. The research suggests that targeting both KRAS and SOS1 could be a promising strategy for improving clinical responses to KRAS inhibitors. [Extracted from the article]

pHi-Tech Animal Health Technologies Ltd. has been issued a patent for an intranasal administration device. The device is designed to administer medications to animals in a quick and efficient manner, reducing operator error and fatigue. It includes a hand-held unit with a spray head, a control unit, and one or more containers for holding medications. The device can be used to administer a single medication or multiple medications, and it has features such as adjustable spray droplet size and a mechanism for recording each administration. The patent provides detailed descriptions of the device and its components. [Extracted from the article]

A patent has been issued to Phibro Animal Health Corporation for strains of bacillus that can inhibit foodborne pathogens. The patent describes a method of reducing foodborne disease by applying or feeding these strains to living animals, animal carcasses, or cuts of meat. Specific strains of bacillus are identified as particularly effective in inhibiting Vibrio. The patent claims include processes for producing food products and inhibiting specific foodborne pathogens such as Salmonella and Escherichia coli. This invention aims to provide a new and effective method of reducing foodborne disease without the use of toxic antibacterial agents or techniques that are unfavorably perceived by the public. [Extracted from the article]

A recent article discusses the Drug Design & Development Seminar (DDDS) held in 2024, which focuses on animal parasitic diseases and conditions. The seminar brings together experts in human and veterinary parasitology to explore One Health approaches to combating parasitic diseases. The article highlights the keynote lectures and scientific talks from the three-day meeting. The research has been peer-reviewed and provides valuable insights into the field of animal parasitic diseases. [Extracted from the article]